Abstract
Asthma is a multifactorial, heterogeneous disease that has a challenging management. It can be divided in non-allergic and allergic (usually associated with house dust mites (HDM) sensitization). There are several treatments options for asthma (corticosteroids, bronchodilators, antileukotrienes, anticholinergics,…); however, there is a subset of patients that do not respond to any of the treatments, who can display either a T2 or a non-T2 phenotype. A deeper understanding of the differential mechanisms underlying each phenotype will help to decipher the contribution of allergy to the acquisition of this uncontrolled severe phenotype. Here, we aim to elucidate the biological pathways associated to allergy in the uncontrolled severe asthmatic phenotype. To do so, twenty-three severe uncontrolled asthmatic patients both with and without HDM-allergy were recruited from Hospital Universitario de Gran Canaria Dr. Negrin. A metabolomic fingerprint was obtained through liquid chromatography coupled to mass spectrometry, and identified metabolites were associated with their pathways. 9/23 patients had uncontrolled HDM-allergic asthma (UCA), whereas 14 had uncontrolled, non-allergic asthma (UCNA). 7/14 (50%) of the UCNA patients had Aspirin Exacerbated Respiratory Disease. There were no significant differences regarding gender or body mass index; but there were significant differences in age and onset age, which were higher in UCNA patients; and in total IgE, which was higher in UCA. The metabolic fingerprint revealed that 103 features were significantly different between UCNA and UCA (p < 0.05), with 97 being increased in UCA and 6 being decreased. We identified lysophosphocholines (LPC) 18:2, 18:3 and 20:4 (increased in UCA patients); and deoxycholic acid and palmitoleoylcarnitine (decreased in UCA). These metabolites were related with a higher activation of phospholipase A2 (PLA2) and other phospholipid metabolism pathways. Our results show that allergy induces the activation of specific inflammatory pathways, such as the PLA2 pathway, which supports its role in the development of an uncontrolled asthma phenotype. There are also clinical differences, such as higher levels of IgE and earlier onset ages for the allergic asthmatic group, as expected. These results provide evidences to better understand the contribution of allergy to the establishment of a severe uncontrolled phenotype.
Introduction
Asthma is a heterogenous, multifactorial respiratory disease that is characterized by wheezing, shortness of breath, chest tightness and coughing (). It affects around 1–18% of the population worldwide, significantly reducing their quality of life ().
Asthma management is a challenge due to its complexity. In fact, there are multiple phenotypes, which are defined according to the clinical manifestation of the disease, as well as endotypes defined according to the underlying mechanisms. Thus, efforts to define homogenous phenotypes of asthma based on their underlying characteristics, have been pushed in the last years (–).
Allergic asthma has been deeply studied over the years. Around 80% of childhood-onset asthma and more than 50% of asthmatic adult patients suffer from allergic asthma (). It has an early onset, usually in childhood, that commonly persists throughout life (, ), and is characterized by a type 2 inflammatory profile, dominated by IL-4, IL-5, IL-9 and IL-13, Th2 cells, eosinophils, and IgE producing plasma cells (). On the other hand, non-allergic or intrinsic asthma is poorly understood (). It usually appears in adulthood, normally around 30–40 years old (). Inflammatory profiles vary among patients, which can be type 2-high or low; and multiple effector cells might be involved, including eosinophils, neutrophils, both, or none (paucigranulocitic asthma) (, ). Moreover, it is usually associated with aspirin-exacerbated respiratory disease (AERD), a non-allergic intolerance to non-steroidal anti-inflammatory drugs (NSAIDs) related to cyclooxygenase (COX)-1. Patients with AERD experiment worsened asthma symptoms while taking this kind of medications, and they usually present nasal polyps (, ).
Treatment for asthmatic patients is complex and is prescribed in a step by step approach regarding GINA guidelines (). Mild allergic asthmatic patients' symptoms control involves either topical or inhaled corticosteroids, usually in combination with short- and long-acting bronchodilators, antileukotrienes, anticholinergics, among other pharmacological drugs, and/or allergen-specific immunotherapy (AIT); while for the more severe ones, systemic corticosteroids and add-on biological therapy targeting type 2 inflammation mediators are also needed. Currently, anti-IgE (omalizumab), anti-IL-5 (mepolizumab, reslizumab), anti-IL-5Rα (benralizumab) and anti-IL-4Rα (dupilumab) are approved for asthmatic patients (), and others, such as anti-TSLP (tezepelumab) are currently under research. Still, there is a subset of asthmatic patients that do not respond to any of these treatments and remain uncontrolled, suffering several exacerbations and hospitalizations every year, which leads to a very low quality of life. In fact, this subset of patients involves allergic and non-allergic patients.
On the other hand, type 2-low non-allergic asthmatic patients do not have any medication that specifically targets their underlying characteristics. Although macrolides have used to treat these patients, they have shown limited success; and a continued use is frowned upon due to antibiotic resistance dangers ().
Overall, uncontrolled asthma remains a concern, as these patients usually present more comorbidities, a lower quality of life and higher mortality rates (). Additionally, evidence regarding the role of allergy in the evolution of asthmatic severity is still lacking.
Allergic asthma usually presents sensitization to house dust mites (HDM). There are reports that up to 85% of asthmatic patients are sensitized to HDM (). It has been recently shown that sensitization to HDM is associated with asthma severity and a lack of disease control in children (). HDM are arachnids that live in tropical areas with high humidity and temperate climates (, ); but are present worldwide and widely populate clothes and bed linens (). Their association with asthma is hypothesized to be related to the physicochemical properties of HDM allergens (such as Der p 1, Der p 2, Der p 21), which include proteases and immune system mimickers that can activate TLR4 responses (). Thus, these proteins might be able to, first, damage the epithelium, and then, activate the immune system, eliciting an immune response, especially in children with an immature epithelial barrier. In fact, respiratory infections in childhood are associated with a higher risk of developing asthma (). Moreover, it has been recently described that Der p 1 elicits a differential metabolic response in an in vitro model of lung epithelium between underdeveloped (2 days of culture) and mature (7 days of culture) tissue ().
However, despite the fact that allergic asthma is the most common phenotype of asthma, and that sensitization to HDM is the most common among these patients, there are asthmatic patients that do not have concomitant allergy, even in areas where HDM exposure is high, such as tropical climates () or high-humidity areas such as islands. One of these regions is the Canary Islands, in Spain, where the HDM exposome has been characterized in depth (, , , ). The reason why some patients do not get sensitized to HDM, but do develop severe uncontrolled asthma without allergy, is unknown; although the fact that lots of these patients have a family history of asthma might be related. Also unknown are the implications of allergy in the development and evolution of asthma. Thus, we aim to decipher the role of allergic inflammation in the pathogenesis of uncontrolled asthma.
Materials and methods
Patients
The study was approved by the Ethics Committee of the Hospital on 4th/February/2016 (code: 160009). Twenty-three severe uncontrolled asthmatic patients with and without allergy were recruited in the Hospital Universitario de Gran Canaria doctor Negrin (Las Palmas de Gran Canaria, Spain). Allergic status was assessed by skin-prick test to a set of HDM allergens (Dermatophagoides pteronyssinus, Dermatophagoides farinae, Blomia tropicalis, Acarus siro, Lepidoglypus destructor and Tyrophagus putrescentiae) and the analysis of clinical history; and patients were classified as allergic, if they were sensitized to HDM (and, possibly, to other allergens) and as non-allergic if they had no known sensitizers. Severity was defined according to the GINA guidelines; patients included were at least on step 4–5 of medication and did not respond to the treatments approved at the date of inclusion (including high doses of inhaled and systemic corticosteroids and/or anti-IgE). They also had around 5 exacerbations per year.
Differences in age, onset age, BMI and total IgE in patients were analyzed using Mann-Withney U test, as the allergic group had <10 patients, while gender, number of smokers and number of patients with AERD were analyzed by Fisher's Exact, using GraphPad Prism v9.3.1 for Windows (GraphPad Software, San Diego, California USA, www.graphpad.com).
Metabolomic analysis
The metabolomic analysis has already been thoroughly described elsewhere (, ). Briefly, serum samples were measured in batches using an Agilent High Performance Liquid Chromatography system (Agilent 1200 series) coupled with a quadrupole- time of flight (QTOF) analyser system (Q-ToF MS 6520) (Agilent Technologies, Waldbronn, Germany), in positive and negative ionization modes (ESI + and ESI -, respectively). A quality control sample (QC) prepared by mixing equal volumes of a set of samples was measured throughout the analytical run. The HPLC system was equipped with a degasser, two binary pumps, and a thermostated autosampler. For the analysis, 10 μL of sample were injected into a Discovery HS C18 (2.1 × 150 mm, 3.0μm; Supelco, Sigma Aldrich, Germany), maintained at 40°C. The flow rate was set at 0.6 mL/min. The elution gradient involved a mobile phase consisting of: (A) 0.1% v/v formic acid (FA) in water and (B) 0.1% v/v FA in acetonitrile. The initial conditions were set at 25% phase B, which increased linearly to 95% phase B in 35 min, and then returned to the initial conditions in 1 min, which were held for 9 min for column reconditioning. Samples were analyzed in both ESI+ and ESI− modes. The capillary voltage was set at 3500 for ESI+ and 4000V for ESI−. The drying gas flow rate was 10.5 L/min at 330°C and gas nebulizer at 52 psi; fragmentor voltage was 175 V; skimmer and octopole radio frequency voltages were set to 65 and 750 V, respectively. A full scan from 100 to 1200 m/z for both modes was performed. MS spectra were collected in the centroid mode at a scan rate of 1.2 Hz. Automatic MS recalibration during batch analysis was carried out introducing a reference standard into the source via a reference sprayer valve. Reference masses for ESI+ were purine (m/z = 121.0508) and HP-0921 (m/z = 922.0097), whereas for ESI− TFA were NH4 (m/z = 119.0363) and HP-0921 (m/z = 966.0007).
Multivariate analysis was performed using SIMCA v.16.0 (Sartorius Stedim Data Analytics). A Principal Component Analysis (PCA) model was used to evaluate data quality and find patterns in samples. Likewise, Partial Least Square Discriminant Analysis (PLS-DA) and Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) supervised models were used to classify the samples and to evaluate differences between groups. Models were evaluated using R2 and Q2 parameters which are the classification and prediction capacity, respectively.
Significant features were selected after pair-wise comparisons using two-tailed Mann-Whitney U test with an FDR correction using an in-house script for Matlab R2015a software (Mathworks, Natick, Massachusetts, USA); and used to build a Hierarchical Clustering Heatmap (HCA), with MetaboAnalyst 5.0 online tool (https://www.metaboanalyst.ca).
Metabolite annotation was performed by comparison with online platform CEU Mass Mediator 3.0 (–) for data bases, and confirmed through tandem mass spectrometry (MS/MS). LC-MS/MS was performed in a similar LC-Q-ToF-MS instrument than the original experiment (Agilent series 1290 HPLC and series 6550 Q-ToF, respectively); and the method for the new equipment, which has been previously described (, ), was adapted to be as close as possible to the original method used. In this analysis, the HPLC system was equipped with a degasser, two binary pumps, and a thermostated autosampler. Briefly, 2 μL of sample were injected into a Zorbax C18-Extend USH BD06804 column (2.1 × 150 mm, 5.0 μm; Agilent Technologies), maintained at 60 °C. The flow rate was set at 0.6 mL/min. The elution gradient involved a mobile phase with the same components than those of the previous analysis, and the initial conditions were set at 5% phase B, which increased linearly to 80% phase B in 7 min, and then to 100% phase B in 4.5 min. Then it returned to the initial conditions in 0.5 min, which were held for 3 min. The capillary voltage was set at 3000 for ESI+ and 4000V for ESI−. The drying gas flow rate was 12 L/min at 250°C. and gas nebulizer, fragmentor voltage, skimmer and octupole radio frequency were set as in the LC-MS analysis. MS/MS spectra were collected in the centroid mode; ions were targeted using the narrow m/z window (1.3 Da) and 20 eV of energy for fragmentation on the quadrupole. To obtain the newer retention time (RT) for this shorter method, samples were first run for LC-MS; then, m/z were matched with their newer RT. Some of the peaks could not be matched with the new RTs. Finally, comparison of the structure proposed against the obtained fragments led to the confirmation of the identity.
An enrichment analysis was performed using MetaboAnalyst 5.0 online tool (https://www.metaboanalyst.ca). Moreover, pathways of the significant identified compounds were obtained using IMPaLA (v 12.0) online tool (http://impala.molgen.mpg.de/).
Results
Patients
A total of 23 patients, 9 allergic to HDM and 14 non-allergic, were recruited for metabolomic analysis. Clinical characteristics of the groups can be found on Table 1.
Table 1
| UCNA | UCA | |
|---|---|---|
| n | 14 | 9 |
| Age | 62.1 ± 2.8 | 47 ± 4.7** |
| Onset age | 29.4 ± 2.9 | 9.6 ± 2.1**** |
| Sex (F/M) | 13/1 | 6 / 3 |
| BMI | 29.7 ± 1.4 | 27.3 ± 1.4 |
| Current smokers | 0 | 0 |
| Total IgE | 257.9 ± 138.2 | 683.2 ± 222.2** |
| AERD (%) | 7 (50%) | 0 |
Clinical characteristics of the recruited patients.
BMI, body mass index; AERD, Aspirin Exacerbated Respiratory Disease.
*p-value < 0.05;
p-value < 0.01;
***p-value < 0.001;
p-value < 0.0001.
Non-allergic uncontrolled asthmatic patients (UCNA) were older and had a later onset of asthma than allergic uncontrolled asthmatic patients (UCA) (62.1 ± 2.8 vs. 47 ± 4.7, p < 0.01, and 29.4 ± 2.9 vs. 9.6 ± 2.1, p < 0.0001, respectively). UCNA also had lower levels of total IgE (257.9 ± 138.2 vs. 683.2 ± 222.2, p < 0.01), as expected. None of the patients were active smokers.
Moreover, 7 (50%) of the UCNA patients suffered AERD, 1 (7%) reported nasal polyps without NSAIDs hypersensitivity besides asthma, and 1 (7%) suffered from NSAIDs hypersensitivity without nasal polyps. On the other hand, from UCA patients, only 1 (11%) had NSAIDs hypersensitivity, and none had nasal polyps.
Overall, our findings, as expected, demonstrate significant differences in clinical and demographic features between both groups.
Metabolomic analysis reveals distinct phenotypes for allergic and non-allergic uncontrolled asthma
After appropriate data processing, a total number of 1,327 features (593 for ESI– and 734 for ESI+) were obtained for the metabolomic profiling of serum. Quality of the data was assessed by grouping of QC samples on a non-supervised PCA model (Figure 1) proving that the variability of the samples was biological and not due to the technique. Then, both groups were compared using a multivariant analysis (Figure 2). We found that UCA patients tended to cluster in the ESI- plot (Figure 2, left) even if the PCA models did not completely separate both groups. As for the PLS-DA and OPLS-DA supervised models, only the ones obtained with the ESI- mode data were valid (upper part of Figure 2); and they had R2 and Q2 parameters of 0.85 and 0.55, for the PLS-DA mode (Figure 2, center), and 0.91 and 0.4, on the OPLS-DA model, where 100% of UCA samples and 64% of UCNA were correctly classified (Figure 2, right).
Figure 1
Figure 2
Afterwards, we performed an univariant analysis with Mann Whitney-U (as the allergic group had <10 patients) and obtained a total of 83 (for ESI–) and 20 (for ESI+) significantly different signals. Most of them (97) were increased in UCA patients compared to UCNA patients. These 103 features were used to build HCA heatmap (Figure 3). As shown, this model was able to correctly classify most of the patients (21 out of 23), grouping all UCA + 2 UCNA patients together (on the left) and the rest of the UCNA patients on the other branch.
Figure 3
Lipid metabolism, specifically for steroids and phosphocholines, lead the differences among groups
We wanted to identify which were the specific features responsible for the separation of these groups. Thus, we performed a tandem MS/MS analysis and compared the obtained fragmented features with fragmentation spectra when available. In addition, manual identification was performed based on previous publications (–37). From the 103 features, we were able to identify 14, with 13 of them having a unique m/z@RT (Table 2). These included steroids (hormones, bile acids, vitamins), lysophosphocholines, and a carnitine, which were all increased in UCA compared to UCNA, with the exception of deoxycholic acid and palmitoleoylcarnitine, which were decreased in UCA. Trajectories of some relevant metabolites can be found in Figure 4.
Table 2
| No. | Technique | Biological category | Compound | m/z | Mass (Da) | RT (min) | Formula | Error (ppm) | Adduct | CV in QCs (%) | % Change (UCA) | p-value | p-value (BH) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LC-MS- | Vitamins | 1α,25-dihydroxy-2α-(3-hydroxypropoxy)vitamin D3 OR isomers | 489.3552 | 490.363 | 30.47 | C30H50O5 | −5.7 | M-H | 6.7 | 37.3 | 0.0105 | 0.1298 |
| 2 | LC-MS- | Steroids | 5α-Dihydrotestosterone sulfate OR isomers | 369.1738 | 370.1816 | 4.59 | C19H30O5S | 0.5 | M-H | 6.3 | 74.3 | 0.0070 | 0.1021 |
| 3 | LC-MS- | Steroids | 5α-Dihydrotestosterone sulfate OR isomers | 369.1736 | 370.1814 | 8.52 | C19H30O5S | 0 | M-H | 5.7 | 77 | 0.0070 | 0.1021 |
| 4 | LC-MS- | Steroids | 5α-Dihydrotestosterone sulfate OR isomers | 369.1738 | 370.1816 | 10.63 | C19H30O5S | 0.5 | M-H | 7.4 | 78.7 | 0.0007 | 0.0915 |
| 5 | LC-MS- | Steroids | 17α,20α-Dihydroxycholesterol OR isomers | 463.3426 | 418.3449 | 29.92 | C27H46O3 | 0.5 | M+FA-H | 11.3 | 36 | 0.0154 | 0.1629 |
| 6 | LC-MS- | Steroids | Androsterone 3-glucuronide OR isomers | 465.2496 | 466.2574 | 7.81 | C25H38O8 | 1.5 | M-H | 6.2 | 66.1 | 0.0030 | 0.0915 |
| 7 | LC-MS- | Steroids | Androsterone 3-glucuronide OR isomers | 465.2463 | 466.2541 | 8.1 | C25H38O8 | −5.6 | M-H | 6.2 | 52.6 | 0.0127 | 0.1453 |
| 8 | LC-MS- | Steroids | Androsterone 3-glucuronide OR isomers | 465.2474 | 466.2552 | 9.61 | C25H38O8 | −3.2 | M-H | 9.8 | 27 | 0.0154 | 0.1629 |
| 9 | LC-MS- | Bile acids | Deoxycholic acid OR isomers | 437.2901 | 392.2924 | 14.73 | C24H40O4 | −0.5 | M+FA-H | 5.4 | −385.8 | 0.0222 | 0.2053 |
| 10 | LC-MS- | Phospholipids | Phosphocholine (18:2/0:0) | 504.3085 | 519.332 | 16.97 | C26H50NO7P | −0.9 | M-CH3 | 9.6 | 29.5 | 0.0374 | 0.2862 |
| 11 | LC-MS- | Phospholipids | Phosphocholine (18:3/0:0) | 562.3137 | 517.316 | 15.63 | C26H48NO7P | −1.5 | M+FA-H | 12.7 | 35.3 | 0.0374 | 0.2862 |
| 12 | LC-MS- | Phospholipids | Phosphocholine (20:4/0:0) | 656.3182 | 543.3332 | 17.12 | C28H50NO7P | 1.2 | M+TFA-H | 27.4 | 26.6 | 0.0265 | 0.2272 |
| 13 | LC-MS- | Phospholipids | Phosphocholine (0:0/20:4) | 614.3483 | 569.3506 | 18.59 | C30H52NO7P | 4.4 | M+FA-H | 20.9 | 35.7 | 0.0265 | 0.2272 |
| 14 | LC-MS+ | Carnitines | Palmitoleoyl carnitine | 398.3269 | 397.3191 | 15.95 | C23H43NO4 | −0.3 | M+H | 11.3 | −60.5 | 0.0428 | 0.9027 |
Physicochemical characteristics of significant annotated signals in metabolomics through LC-MS/MS between UCNA and UCA groups.
FA, Formic Acid; TFA, Trifluoroacetic acid; CV, Coefficient of variation; QC, Quality control. The CV in the injections of the QC sample assures that the metabolites were measured throughout the experiment in a constant and reproducible manner. In this sense, if the variations in QCs are lower than 30%, it means that the variations found in a particular metabolite are due to the true increase or decrease between the comparison groups. Thus, the % of CV in QCs should be always less than the % change between groups for each metabolite, which assesses that the results of this experiment are reliable.
Figure 4
Finally, we performed an enrichment analysis to obtain the chemical subclasses that were changed in our samples (Figure 5); where the more changed classes were lysophosphocholines (LPC) and steroids.
Figure 5
Moreover, we tried to relate these specific compounds to the pathways in which they are involved using IMPALA (Table 3). We found 155 possible related pathways, 44 of them being significantly different, including the phospholipase A2 (PLA2) pathway, steroid hormone biosynthesis, phosphatidyl choline catabolism and acyl chain remodeling, or lipids metabolism, among others.
Table 3
| Pathway name | p-value | p-value (BH) | Number of genes identified in pathway | Pathway source |
|---|---|---|---|---|
| Osteoblast signaling | 0.00383 | 1 | 1 | Wikipathways |
| Retinoic acid receptors-mediated signaling | 0.00383 | 1 | 1 | PID |
| Signaling events mediated by the hedgehog family | 0.00383 | 1 | 1 | PID |
| Rheumatoid arthritis - Homo sapiens (human) | 0.00574 | 1 | 1 | KEGG |
| STING pathway in kawasaki-like disease and COVID-19 | 0.00765 | 1 | 1 | Wikipathways |
| Steroid hormone biosynthesis - homo sapiens (human) | 0.0103 | 1 | 2 | KEGG |
| Acyl chain remodeling of CL | 0.0115 | 1 | 1 | Reactome |
| Acyl chain remodeling of PC | 0.0115 | 1 | 1 | Reactome |
| Hydrolysis of LPC | 0.0115 | 1 | 1 | Reactome |
| Phosphatidylcholine catabolism | 0.0115 | 1 | 1 | Wikipathways |
| RXR and RAR heterodimerization with other nuclear receptor | 0.0115 | 1 | 1 | PID |
| COPI-independent golgi-to-ER retrograde traffic | 0.0133 | 1 | 1 | Reactome |
| phospho-PLA2 pathway | 0.0133 | 1 | 1 | Reactome |
| Vitamins A and D - action mechanisms | 0.0133 | 1 | 1 | Wikipathways |
| Vitamin D (calciferol) metabolism | 0.0152 | 1 | 1 | Reactome |
| Golgi-to-ER retrograde transport | 0.0171 | 1 | 1 | Reactome |
| Metabolism of steroids | 0.0171 | 1 | 2 | Reactome |
| Vitamin D metabolism | 0.0171 | 1 | 1 | Wikipathways |
| GPCR downstream signalling | 0.0185 | 1 | 2 | Reactome |
| 1_25-dihydroxyvitamin D3 biosynthesis | 0.019 | 1 | 1 | HumanCyc |
| Choline metabolism in cancer - homo sapiens (human) | 0.019 | 1 | 1 | KEGG |
| HDL remodeling | 0.019 | 1 | 1 | Reactome |
| Plasma lipoprotein remodeling | 0.019 | 1 | 1 | Reactome |
| Metabolism of lipids | 0.0197 | 1 | 3 | Reactome |
| Ca-dependent events | 0.0209 | 1 | 1 | Reactome |
| Intra-Golgi and retrograde Golgi-to-ER traffic | 0.0209 | 1 | 1 | Reactome |
| Vitamins | 0.0209 | 1 | 1 | Reactome |
| Vitamin D3 (cholecalciferol) metabolism | 0.0228 | 1 | 1 | EHMN |
| Plasma lipoprotein assembly_ remodeling_ and clearance | 0.0247 | 1 | 1 | Reactome |
| Vitamin D-sensitive calcium signaling in depression | 0.0247 | 1 | 1 | Wikipathways |
| Signaling by GPCR | 0.0264 | 1 | 2 | Reactome |
| RAS and bradykinin pathways in COVID-19 | 0.0266 | 1 | 1 | Wikipathways |
| G-protein mediated events | 0.0303 | 1 | 1 | Reactome |
| PLC beta mediated events | 0.0303 | 1 | 1 | Reactome |
| 16p11.2 proximal deletion syndrome | 0.0322 | 1 | 1 | Wikipathways |
| Drug Induction of Bile Acid Pathway | 0.034 | 1 | 1 | Wikipathways |
| Membrane Trafficking | 0.0378 | 1 | 1 | Reactome |
| Opioid Signaling | 0.0378 | 1 | 1 | Reactome |
| Recycling of bile acids and salts | 0.0378 | 1 | 1 | Reactome |
| Linoleate metabolism | 0.0396 | 1 | 1 | EHMN |
| Vitamin A and carotenoid metabolism | 0.0396 | 1 | 1 | Wikipathways |
| ADORA2B mediated anti-inflammatory cytokines production | 0.0415 | 1 | 1 | Reactome |
| G alpha (s) signalling events | 0.047 | 1 | 1 | Reactome |
| Glycerophospholipid metabolism - Homo sapiens (human) | 0.047 | 1 | 1 | KEGG |
Significantly enriched metabolic pathways in UCA patients compared to UCNA (p < 0.05).
Discussion
The stratification of asthma in groups with the idea of finding the underlying mechanisms has been pursued since a long time ago. Particularly, finding the endotypes of uncontrolled severe asthma is crucial, as the therapeutic options for these patients are limited and often do not work (38). Particularly, in non-allergic asthma, there are limited available options, as this phenotype has been understudied (39, 40). Here, we aimed to elucidate the contribution of allergy to the uncontrolled severe allergic phenotype.
Clinical differences in allergic and non-allergic non-Th2 asthma have been already described in previous publications (, ). In our research, we found that UCNA patients were older, had a later onset age, and lower levels of total IgE than UCA patients, which is consistent with these previous publications. Nonetheless, this should be taken into account, as these could act as confounding factors given the complexity of this asthma model. Moreover, AERD was clearly associated with non-allergic asthma, as has been already described (, ). It is known that NSAIDs intolerance is not related to an increase in atopy (41). Despite the risk of AERD patients to develop a systemic reaction and the worsening of symptoms after NSAIDs intake, there is a lack of studies on the underlying mechanisms of this syndrome. Interestingly, it has been described that AERD was associated with an increase in eicosanoids compared to aspirin-tolerant asthma (42). However, the allergic status of non-AERD patients was not described; thus, it remains unclear if AERD and allergy activate similar pathways in asthma, and further studies investigating this should be pursued.
Regarding the metabolomic analysis, we found a distinctive metabolic profile between UCA and UCNA patients, which was characterized by a substantial increase in a set of LPCs, including LPC 18:2 and LPC 20:4, two of the most abundant LPCs in plasma (43). These LPCs are related to the PLA2 pathway, which, together with a reduction in palmitoleylcarnitine, point toward the arachidonic acid pathway as critical to understand the contribution of allergy to these settings.
Changes in LPCs have already been described in asthma and allergy (44–47) and extensively associated with inflammatory response (48). Increases in LPC 18:2 and 20:4 have been observed in the active group compared with the placebo treatment in grass-pollen allergic patients after 2 years of sublingual immunotherapy (49), pointing toward an induction of inflammation.
It has been described that mast cells, alveolar macrophages and neutrophils can secrete sPLA2, a process that is triggered by allergen challenge (50). Moreover, during inflammation, sPLA2 is associated with high-density lipoproteins (HDL), and can significantly alter HDL composition, which, in inflammation, are enriched in LPCs, including LPC 18:2. It has been demonstrated that these LPCs can act as mediators and impair platelet aggregation (51). There is increasing evidence of platelets playing a role in asthma (52) and allergy (53, 54).
LPC 20:4 has been associated with increased release of inflammatory cytokines in endothelial cells, triggering M2 or alternative macrophage polarization (55). Furthermore, PLA2 hydrolyses phospholipids and releases LPC and free fatty acids; including arachidonic acid (56–58). Arachidonic acid (AA, C 20:4), which was found increased in its LPC form in UCA, is a precursor of eicosanoids (prostaglandins, lipoxins, leukotrienes), resolvins, and protectins, all of them involved in the regulation of immune response (59). These are known to play a role in asthma, allergy, and other inflammatory pathologies (60, 61).
Interestingly, we found that palmitoleoylcarnitine was decreased in UCA patients. A decrease in carnitines together with an increase in LPCs has been described in severe allergy compared to controls (53).
Overall, our results show that allergic inflammation in uncontrolled asthma leads to a significant alteration of various inflammatory routes, including the AA pathway, along with a dysregulation of LPC mediators, pointing toward these two factors as allergic contributors in asthma.
Steroid biosynthesis was also found increased in UCA patients, which has also been described in allergic asthma compared to healthy controls (47). Steroids have been demonstrated to play a role in the activation of immune system and in the development of asthma (62); thus this might be related with the higher activation shown. Some studies have linked inhaled corticosteroids with a suppression of the adrenal gland (63). However, all our patients were treated with a combination of inhaled corticosteroids and a long-acting bronchodilators; and there were no differences in topical or oral corticosteroid intake among groups. Moreover, there also seemed to be an involvement of bile acids. The role of bile acids in inflammatory diseases is becoming increasingly clearer (64); in particular, there seems to be a connection between respiratory diseases and gastroesophageal reflux; and bile acid increases have been reported previously (45).
Interestingly, deoxycholic acid was found reduced in UCA patients compared to UCNA. We have previously reported a decrease in deoxycholic acid in asthma according to severity (). This secondary bile acid has been demonstrated to stimulate the production of inflammatory cytokines in an in vitro epithelial airway cell culture; and to promote inflammation in animal models either by inducing inflammatory cytokine production (65), activation of the inflammasome (66) and inducing the dysbiosis of gut microbiota (67). Thus, steroid metabolism seems to be differential and a key player in inflammation for non-allergic asthma.
Nontheless, it is important to consider that this is an exploratory study. Future projects including more samples that explore other aspects of asthma are needed. For example, there is increasing evidence that sensitization to Staphylococcus aureus enterotoxins is related with the development of severe asthma and disease exacerbations (68), and with nasal polyps (69). Thus, sensitization to staphylococcal enterotoxins might play a role in non-allergic asthma pathogenesis, and its analysis could be helpful in understanding the influence of asthma in this disease.
Conclusions
Overall, we found that allergic inflammation elicits a differential inflammatory phenotype in severe uncontrolled asthma patients. This inflammation is related to the arachidonic acid and the PLA2 pathways and is marked by a distinctive metabolomic profile in both groups. Moreover, this study highlights the need of further studies to better elucidate the underlying pathways in non-allergic asthma, as novel therapeutic targets unrelated to type 2 inflammation are needed for a better treatment in these patients.
Funding
This work was supported by ISCIII (PI19/00044 and PI18/01467), cofounded by FEDER Investing in your future for the thematic network and cooperative research centers ARADyAL (RD16/0006/0015) and RICORS Red de Enfermedades Inflamatorias (REI) (RD21/0002/0008), the Ministry of Science and innovation in Spain (PCi2018-092930) co-funded by the European program ERA HDHL – Nutrition & the Epigenome, Project Dietary Intervention in Food Allergy: Microbiome, Epigenetic and Metabolomic Interactions DIFAMEM and Fundación Mutua Madrileña (AP177712021). MD and JR-C were supported by FPI-CEU predoctoral fellowships and DO was funded by a postdoctoral research fellowship from the European program ERA HDHL – Nutrition & the Epigenome, Project Dietary Intervention in Food Allergy: Microbiome, Epigenetic and Metabolomic Interactions DIFAMEM.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ebi.ac.uk/metabolights/, MTBLS1133.
Ethics statement
The studies involving human participants were reviewed and approved by Comité de ética de la Investigación Hospital Universitario de Gran Canaria Check dot after Dr. Negrin Hospital Barranco de la Ballena s/n. Hospital Universitario de Gran Canaria Dr. Negrín, Edificio de Investigación, Planta principal. 35019 Las Palmas de Gran Canaria (study code: 160009). The patients/participants provided their written informed consent to participate in this study.
Author contributions
ME was the PI and together with DB and AV designed the study and supervised the research. TC, AA, and HG recruited the patients and obtained the samples. MD, DO, JR-C, AV, and CB performed the metabolomic analysis and data treatment. MD performed analysis of the results together with DO. All authors contributed to the writing of the manuscript and have given approval to the final version of the manuscript.
Acknowledgments
We would like to thank all institutions involved: Institute of Applied Molecular Medicine (IMMA, Universidad CEU San Pablo, CEU Universities, Madrid), Center of Metabolomics and Bioanalysis (CEMBIO, Universidad CEU San Pablo, CEU Universities, Madrid), and the Hospital Universitario de Gran Canaria Dr. Negrín (Las Palmas de Gran Canaria, Spain).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. (2022). Available online at: www.ginasthma.org (accessed June 26, 2022).
2.
VosTLimSSAbbafatiCAbbasKMAbbasiMAbbasifardMet al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. (2020) 396:1204–22. 10.1016/S0140-6736(20)30925-9
3.
WenzelSE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. (2012) 18:716–25. 10.1038/nm.2678
4.
AgacheIAkdisCJutelMVirchowJC. Untangling asthma phenotypes and endotypes. Allergy. (2012) 67:835–46. 10.1111/j.1398-9995.2012.02832.x
5.
CampoPRodríguezFSánchez-GarcíaSBarrancoPQuirceSPérez-FrancésCet al. Phenotypes and endotypes of uncontrolled severe asthma: new treatments. J Investig Allergol Clin Immunol. (2013) 23:76–88.
6.
Akar-GhibrilNCasaleTCustovicAPhipatanakulW. Allergic endotypes and phenotypes of asthma. J Allergy Clin Immunol Pract. (2020) 8:429–40. 10.1016/j.jaip.2019.11.008
7.
HolgateSTWenzelSPostmaDSWeissSTRenzHSlyPD. Asthma. Nat Rev Dis Prim. (2015) 1:1–22. 10.1016/B978-0-12-415847-4.00096-3
8.
Licona-LimónPKimLKPalmNWFlavellRA. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol. (2013) 14:536–42. 10.1038/ni.2617
9.
EdwardsMRSaglaniSSchwarzeJSkevakiCSmithJAAinsworthBet al. Addressing unmet needs in understanding asthma mechanisms. Eur Respir J. (2017) 49:1602448. 10.1183/13993003.02448-2016
10.
PakkaselaJIlmarinenPHonkamäkiJTuomistoLEAndersénHPiiriläPet al. Age-specific incidence of allergic and non-allergic asthma. BMC Pulm Med. (2020) 20: 9. 10.1186/s12890-019-1040-2
11.
TlibaOPanettieriRA. Paucigranulocytic asthma: uncoupling of airway obstruction from inflammation. J Allergy Clin Immunol. (2019) 143:1287–94. 10.1016/j.jaci.2018.06.008
12.
KennedyJLStonerANBorishL. Aspirin-exacerbated respiratory disease: prevalence, diagnosis, treatment, and considerations for the future. Am J Rhinol Allergy. (2016) 30:407–13. 10.2500/ajra.2016.30.4370
13.
TaniguchiMMitsuiCHayashiHOnoEKajiwaraKMitaHet al. Aspirin-exacerbated respiratory disease (AERD): current understanding of AERD. Allergol Int. (2019) 68:289–95. 10.1016/j.alit.2019.05.001
14.
Menzies-GowANMcBrienCUnniBPorsbjergCMAl-AhmadMAmbroseCSet al. Real world biologic use and switch patterns in severe asthma: data from the international severe asthma registry and the US CHRONICLE study. J Asthma Allergy. (2022) 15:63–78. 10.2147/JAA.S328653
15.
HinksTSCLevineSJBrusselleGG. Treatment options in type-2 low asthma. Eur Respir J. (2021) 57:1–36. 10.1183/13993003.00528-2020
16.
PetersSPFergusonGDenizYReisnerC. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med. (2006) 100:1139–51. 10.1016/j.rmed.2006.03.031
17.
WangJY. The innate immune response in house dust mite-induced allergic inflammation. Allergy, Asthma Immunol Res. (2013) 5:68–74. 10.4168/aair.2013.5.2.68
18.
OkashaNMSarhanAAAhmedEO. Association between house dust mites sensitization and level of asthma control and severity in children attending Mansoura University Children's Hospital. Egypt J Bronchol. (2021) 15:36. 10.1186/s43168-021-00082-x
19.
Juliá-SerdáGCabrera-NavarroPAcosta-FernándezOMartín-PérezPLosada-CabreraPGarcía-BelloMAet al. High prevalence of asthma and atopy in the Canary Islands, Spain. Int J Tuberc Lung Dis. (2011) 15:536–41. 10.5588/ijtld.10.0303
20.
Julià SerdàGCabrera NavarroPAcosta FernándezOMartín PérezPBatista MartínJAlamo SantanaFet al. High prevalence of asthma symptoms in the Canary Islands: climatic influence?J Asthma. (2005) 42:507–11. 10.1081/JAS-67621
21.
MillerJD. The role of dust mites in allergy. Clin Rev Allergy Immunol. (2019) 57:312–29. 10.1007/s12016-018-8693-0
22.
Sánchez-BorgesMFernandez-CaldasEThomasWRChapmanMDLeeBWCaraballoLet al. International consensus (ICON) on: clinical consequences of mite hypersensitivity, a global problem. World Allergy Organ J. (2017) 10:14. 10.1186/s40413-017-0145-4
23.
López-RodríguezJCRodríguez-CoiraJBenedéSBarbasCBarberDVillalbaMTet al. Comparative metabolomics analysis of bronchial epithelium during barrier establishment after allergen exposure. Clin Transl Allergy. (2021) 11:1–10. 10.1002/clt2.12051
24.
PumhirunPTowiwatPMahakitP. Aeroallergen sensitivity of Thai patients with allergic rhinitis. Asian Pacific J Allergy Immunol. (1997) 15:183–5.
25.
Juliá-SerdáGCabrera-NavarroPAcosta-FernándezOMartín-PérezPGarcía-BelloMAAntó-BoquéJ. Prevalence of sensitization to Blomia tropicalis among young adults in a temperate climate. J Asthma. (2012) 49:349–54. 10.3109/02770903.2012.672611
26.
MenéndezIDerbyshireECarrilloTCaballeroEEngelbrechtJPRomeroLEet al. Saharan dust and the impact on adult and elderly allergic patients: the effect of threshold values in the northern sector of Gran Canaria, Spain. Int J Environ Health Res. (2017) 27:144–60. 10.1080/09603123.2017.1292496
27.
Rodríguez-CoiraJDelgado-DolsetMObesoDDolores-HernándezMQuintásGAnguloSet al. Troubleshooting in large-scale LC-ToF-MS metabolomics analysis: solving complex issues in big cohorts. Metabolites. (2019) 9:247. 10.3390/metabo9110247
28.
Delgado-DolsetMIObesoDRodríguez-CoiraJTarinCTanGCumplidoJAet al. Understanding uncontrolled severe allergic asthma by integration of omic and clinical data. Allergy. (2022) 77:1772–85. 10.1111/all.15192
29.
Gil-de-la-FuenteAGodzienJSaugarSGarcia-CarmonaRBadranHWishartDSet al. CEU mass mediator 30: a metabolite annotation tool. J Proteome Res. (2019) 18:797–802. 10.1021/acs.jproteome.8b00720
30.
Gil de la FuenteAGodzienJFernández LópezMRupérezFJBarbasCOteroA. Knowledge-based metabolite annotation tool: CEU mass mediator. J Pharm Biomed Anal. (2018) 154:138–49. 10.1016/j.jpba.2018.02.046
31.
Mamani-HuancaMde la FuenteAGOteroAGradillasAGodzienJBarbasCet al. Enhancing confidence of metabolite annotation in Capillary Electrophoresis-Mass Spectrometry untargeted metabolomics with relative migration time and in-source fragmentation. J Chromatogr A. (2021) 1635:461758. 10.1016/j.chroma.2020.461758
32.
GarcíaCAGil-de-la-FuenteABarbasCOteroA. Probabilistic metabolite annotation using retention time prediction and meta-learned projections. J Cheminformatics. (2022) 14:1–23. 10.1186/s13321-022-00613-8
33.
SoldevillaBLópez-lópezALens-pardoACarretero-pucheCLopez-gonzalvezALa SalviaAet al. Comprehensive plasma metabolomic profile of patients with advanced neuroendocrine tumors (Nets). diagnostic and biological relevance. Cancers. (2021) 13:2634. 10.3390/cancers13112634
34.
Gil de la FuenteATraldiFSirokaJKretowskiACiborowskiMOteroAet al. Characterization and annotation of oxidized glycerophosphocholines for non-targeted metabolomics with LC-QTOF-MS data. Anal Chim Acta. (2018) 1037:358–68. 10.1016/j.aca.2018.08.005
35.
Gonzalez-RianoCGradillasABarbasC. Exploiting the formation of adducts in mobile phases with ammonium fluoride for the enhancement of annotation in liquid chromatography-high resolution mass spectrometry based lipidomics. J Chromatogr Open. (2021) 1:100018. 10.1016/j.jcoa.2021.100018
36.
DemarqueDPCrottiAEMVessecchiRLopesJLCLopesNP. Fragmentation reactions using electrospray ionization mass spectrometry: an important tool for the structural elucidation and characterization of synthetic and natural products. Nat Prod Rep. (2016) 33:432–55. 10.1039/C5NP00073D
37.
TsugawaHIkedaKTakahashiMSatohAMoriYUchinoHet al. MS-DIAL 4: accelerating lipidomics using an MS/MS, CCS, and retention time atlas. bioRxiv. (2020). 10.1101/2020.02.11.944900
38.
AgacheI. Severe asthma phenotypes and endotypes. Semin Immunol. (2019) 46:101301. 10.1016/j.smim.2019.101301
39.
SeysSFLokwaniRSimpsonJLBullensDMA. New insights in neutrophilic asthma. Curr Opin Pulm Med. (2019) 25:113–20. 10.1097/MCP.0000000000000543
40.
BittarHETYousemSAWenzelSE. Pathobiology of severe asthma. Annu Rev Pathol Mech Dis. (2015) 10:511–45. 10.1146/annurev-pathol-012414-040343
41.
QuiralteJBlancoCCastilloROrtegaNCarrilloT. Anaphylactoid reactions due to nonsteroidal antiinflammatory drugs: clinical and cross-reactivity studies. Ann Allergy, Asthma Immunol. (1997) 78:293–6. 10.1016/S1081-1206(10)63184-5
42.
BanGYChoKKimSHYoonMKKimJHLeeHYParkHSet al. Metabolomic analysis identifies potential diagnostic biomarkers for aspirin-exacerbated respiratory disease. Clin Exp Allergy. (2017) 47:37–47. 10.1111/cea.12797
43.
LiuPChenCChenX. The mechanisms of lysophosphatidylcholine in the development of diseases. Life Sci. (2020) 247:117443. 10.1016/j.lfs.2020.117443
44.
JungJKimS-HLeeH-SChoiGSJungY-SRyuDHet al. Serum metabolomics reveals pathways and biomarkers associated with asthma pathogenesis. Clin Exp Allergy. (2013) 43:425–33. 10.1111/cea.12089
45.
ComhairSAAMcDunnJBennettCFettigJErzurumSCKalhanSC. Metabolomic endotype of asthma. J Immunol. (2015) 195:643–50. 10.4049/jimmunol.1500736
46.
RiedJSBaurechtHStücklerFKrumsiekJGiegerCHeinrichJet al. Integrative genetic and metabolite profiling analysis suggests altered phosphatidylcholine metabolism in asthma. Allergy. (2013) 68:629–36. 10.1111/all.12110
47.
ZhengPBianXZhaiYLiCLiNHaoCet al. Metabolomics reveals a correlation between hydroxyeicosatetraenoic acids and allergic asthma: evidence from three years' immunotherapy. Pediatr Allergy Immunol. (2021) 32:1654–62. 10.1111/pai.13569
48.
ChiurchiùVLeutiAMaccarroneM. Bioactive lipids and chronic inflammation: managing the fire within. Front Immunol. (2018) 9:38. 10.3389/fimmu.2018.00038
49.
Barker-TejedaTCBazireRObesoDMera-BerriatuaLRosaceDVazquez-CortesSet al. Exploring novel systemic biomarker approaches in grass-pollen sublingual immunotherapy using omics. Allergy. (2021) 76:1199–212. 10.1111/all.14565
50.
BansalPGaurSNAroraN. Lysophosphatidylcholine plays critical role in allergic airway disease manifestation. Sci Rep. (2016) 6:2–11. 10.1038/srep27430
51.
CurcicSHolzerMPasterkLKnuplezEEichmannTOFrankSet al. Secretory phospholipase A2 modified HDL rapidly and potently suppresses platelet activation. Sci Rep. (2017) 7:1–12. 10.1038/s41598-017-08136-1
52.
YueMHuMFuFRuanHWuC. Emerging roles of platelets in allergic asthma. Front Immunol. (2022) 13:846055. 10.3389/fimmu.2022.846055
53.
ObesoDMera-BerriatuaLRodríguez-CoiraJRosaceDFernándezPMartín-AntonianoIAet al. Multi-omics analysis points to altered platelet functions in severe food-associated respiratory allergy. Allergy. (2018) 73:2137–49. 10.1111/all.13563
54.
Gomez-CasadoCVillaseñorARodriguez-NogalesABuenoJLBarberDEscribeseMM. Understanding platelets in infectious and allergic lung diseases. Int J Mol Sci. (2019) 20:1730. 10.3390/ijms20071730
55.
AssunçãoLSMagalhãesKGCarneiroABMolinaroRAlmeidaPEAtellaGCet al. Schistosomal-derived lysophosphatidylcholine triggers M2 polarization of macrophages through PPARγ dependent mechanisms. Biochim Biophys Acta Mol Cell Biol Lipids. (2017) 1862:246–54. 10.1016/j.bbalip.2016.11.006
56.
BennettMGilroyDW. Lipid mediators in inflammation. Microbiol Spectr. (2016) 4:MCHD-0035-2016. 10.1128/microbiolspec.MCHD-0035-2016
57.
AritaM. Eosinophil polyunsaturated fatty acid metabolism and its potential control of inflammation and allergy. Allergol Int. (2016) 65:S2–5. 10.1016/j.alit.2016.05.010
58.
BalgomaDAstudilloAMPerez-ChaconGMonteroOBalboaMABalsindeJ. Markers of monocyte activation revealed by lipidomic profiling of arachidonic acid-containing phospholipids. J Immunol. (2010) 184:3857–65. 10.4049/jimmunol.0902883
59.
SokolowskaMRovatiGEDiamantZUntersmayrESchwarzeJLukasikZet al. Current perspective on eicosanoids in asthma and allergic diseases - EAACI Task Force consensus report, part I. Allergy. (2021) 76:114–30. 10.1111/all.14295
60.
PecakMKorošecPKunejT. Multiomics data triangulation for asthma candidate biomarkers and precision medicine. Omi A J Integr Biol. (2018) 22:392–409. 10.1089/omi.2018.0036
61.
NieXWeiJHaoYTaoJLiYLiuMet al. Consistent biomarkers and related pathogenesis underlying asthma revealed by systems biology approach. Int J Mol Sci. (2019) 20:4037. 10.3390/ijms20164037
62.
FuseiniHNewcombDC. Mechanisms driving gender differences in asthma. Curr Allergy Asthma Rep. (2017) 17:19. 10.1007/s11882-017-0686-1
63.
KachrooPStewartIDKellyRSStavMMendezKDahlinAet al. Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma. Nat Med. (2022) 28:814–22. 10.1038/s41591-022-01714-5
64.
ChenMLTakedaKSundrudMS. Emerging roles of bile acids in mucosal immunity and inflammation. Mucosal Immunol. (2019) 12:851–61. 10.1038/s41385-019-0162-4
65.
ChungSJLeeCHLeeHSKimSTSohnUDParkESet al. The role of phosphatidylcholine and deoxycholic acid in inflammation. Life Sci. (2014) 108:88–93. 10.1016/j.lfs.2014.05.013
66.
ZhaoSGongZZhouJTianCGaoYXuCet al. Deoxycholic acid triggers nlrP3 inflammasome activation and aggravates Dss-induced colitis in mice. Front Immunol. (2016) 7:536. 10.3389/fimmu.2016.00536
67.
XuMCenMShenYZhuYChengFTangLet al. Deoxycholic acid - induced gut dysbiosis disrupts bile acid enterohepatic circulation and promotes intestinal inflammation. Dig Dis Sci. (2021) 66:568–76. 10.1007/s10620-020-06208-3
68.
FloraMPernaFAbbadessaSGarzianoFMaffucciRManiscalcoMet al. Basophil activation test for Staphylococcus aureus enterotoxins in severe asthmatic patients. Clin Exp Allergy. (2021) 51:536–45. 10.1111/cea.13772
69.
CuiXYMiaoJLLuHQQiQHChenXIXuJet al. Serum levels of specific IgE to Staphylococcus aureus enterotoxins in patients with chronic rhinosinusitis. Exp Ther Med. (2015) 9:1523–7. 10.3892/etm.2015.2247
Summary
Keywords
asthma, metabolomics, allergy, lysophospholipids, bile acids (BAs), HDM-allergy
Citation
Delgado Dolset MI, Obeso D, Rodriguez-Coira J, Villaseñor A, González Cuervo H, Arjona A, Barbas C, Barber D, Carrillo T and Escribese MM (2022) Contribution of allergy in the acquisition of uncontrolled severe asthma. Front. Med. 9:1009324. doi: 10.3389/fmed.2022.1009324
Received
01 August 2022
Accepted
22 August 2022
Published
21 September 2022
Volume
9 - 2022
Edited by
Girolamo Pelaia, Magna Græcia University, Italy
Reviewed by
Victor Matheu, Canary Islands University Hospital, Spain; Francesco Perna, Federico II University Hospital, Italy
Updates
Copyright
© 2022 Delgado Dolset, Obeso, Rodriguez-Coira, Villaseñor, González Cuervo, Arjona, Barbas, Barber, Carrillo and Escribese.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: María M. Escribese mariamarta.escribesealonso@ceu.es
This article was submitted to Pulmonary Medicine, a section of the journal Frontiers in Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.